(Q74276899)
English
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cance
scientific article published on 01 January 1998
Statements
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group (English)
R Paridaens
J A Roy
M Nooij
J Klijn
S J Houston
L V Beex
J Vinholes
E Tomiak
A Van Vreckem
C Langenaeken
M Van Glabbeke